Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Change in Account Payables: 2018-2024

Historic Change in Account Payables for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Dec 2024 value amounting to $1.9 million.

  • Arcturus Therapeutics Holdings' Change in Account Payables fell 33.68% to -$5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.6 million, marking a year-over-year increase of 42.24%. This contributed to the annual value of $1.9 million for FY2024, which is 185.57% up from last year.
  • Per Arcturus Therapeutics Holdings' latest filing, its Change in Account Payables stood at $1.9 million for FY2024, which was up 185.57% from -$2.2 million recorded in FY2023.
  • Arcturus Therapeutics Holdings' Change in Account Payables' 5-year high stood at $4.8 million during FY2020, with a 5-year trough of -$3.1 million in FY2022.
  • For the 3-year period, Arcturus Therapeutics Holdings' Change in Account Payables averaged around -$1.1 million, with its median value being -$2.2 million (2023).
  • In the last 5 years, Arcturus Therapeutics Holdings' Change in Account Payables tumbled by 304.68% in 2022 and then soared by 185.57% in 2024.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Change in Account Payables (Yearly) stood at $4.8 million in 2020, then slumped by 115.98% to -$769,000 in 2021, then tumbled by 304.68% to -$3.1 million in 2022, then rose by 28.08% to -$2.2 million in 2023, then surged by 185.57% to $1.9 million in 2024.